Charles River Laboratories Intl. Target of Unusually High Options Trading (NYSE:CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) was the target of some unusual options trading on Tuesday. Stock traders acquired 877 put options on the company. This represents an increase of approximately 1,024% compared to the typical volume of 78 put options.

In related news, VP Birgit Girshick sold 1,051 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $145.55, for a total value of $152,973.05. Following the completion of the transaction, the vice president now owns 18,728 shares in the company, valued at approximately $2,725,860.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.80% of the company’s stock.

Several institutional investors have recently made changes to their positions in CRL. Squar Milner Financial Services LLC lifted its holdings in shares of Charles River Laboratories Intl. by 253.2% during the 3rd quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock valued at $28,000 after buying an additional 157 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of Charles River Laboratories Intl. during the 3rd quarter valued at about $33,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Charles River Laboratories Intl. during the 4th quarter valued at about $34,000. Valeo Financial Advisors LLC lifted its holdings in shares of Charles River Laboratories Intl. by 239.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 241 shares of the medical research company’s stock valued at $37,000 after buying an additional 170 shares during the last quarter. Finally, CNB Bank acquired a new stake in shares of Charles River Laboratories Intl. during the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 95.78% of the company’s stock.

Shares of Charles River Laboratories Intl. stock opened at $171.33 on Thursday. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of 36.77, a P/E/G ratio of 1.77 and a beta of 1.18. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.43 and a quick ratio of 1.20. Charles River Laboratories Intl. has a 52-week low of $123.17 and a 52-week high of $175.25. The stock has a 50-day simple moving average of $156.55 and a 200-day simple moving average of $140.83.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.83 by $0.18. The business had revenue of $691.10 million during the quarter, compared to analyst estimates of $685.46 million. Charles River Laboratories Intl. had a return on equity of 21.52% and a net margin of 9.14%. The firm’s revenue was up 14.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.49 EPS. As a group, equities research analysts predict that Charles River Laboratories Intl. will post 6.55 earnings per share for the current year.

A number of equities research analysts have commented on the company. Robert W. Baird restated an “outperform” rating and set a $185.00 price objective (up from $165.00) on shares of Charles River Laboratories Intl. in a research report on Wednesday. Argus restated a “buy” rating and set a $170.00 price objective on shares of Charles River Laboratories Intl. in a research report on Tuesday, November 19th. KeyCorp raised their price objective on Charles River Laboratories Intl. from $151.00 to $162.00 and gave the stock an “overweight” rating in a research report on Monday, December 9th. Bank of America lowered Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price objective for the company. in a research report on Friday, October 18th. Finally, Cfra raised their price objective on Charles River Laboratories Intl. from $165.00 to $180.00 and gave the stock a “strong-buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories Intl. has a consensus rating of “Buy” and a consensus price target of $168.88.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: What is a stock buyback?

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.